by A recent study conducted by Columbia University researchers has mapped the effects of ketamine on the brain, providing valuable insights into its therapeutic potential. Ketamine, known for both its anesthetic properties and recreational use, has gained recognition as a viable treatment for various medical conditions, including pain management and treatment-resistant depression. The study, published in the journal Cell Reports, shows that long-term ketamine use leads to widespread structural changes in the brain’s dopamine system.
Instead of administering ketamine doses that impact the entire brain, the study suggests that targeting specific areas of the brain could minimize unintended effects on dopamine regions. Raju Tomer, the senior author of the paper, emphasized the importance of this approach to ensure safer and more effective ketamine therapies.
The research found that repeated exposure to ketamine resulted in a decrease in dopamine neurons in the midbrain regions responsible for mood regulation. Conversely, an increase in dopamine neurons was observed in the hypothalamus, which controls basic bodily functions like metabolism and homeostasis. These findings provide insight into why long-term ketamine abuse may lead to symptoms similar to schizophrenia, as well as its potential for treating eating disorders.
Furthermore, the study explored how ketamine affects dopamine networks throughout the brain. Researchers discovered a reduction in dopamine axon density in areas related to hearing and vision, while cognitive centers showed increased dopamine axons. These findings shed light on the dissociative effects associated with ketamine use.
In contrast to previous studies focused on acute exposure, this research examined the effects of daily ketamine use over up to 10 days. Significant alterations in the brain’s dopamine composition were only observed after prolonged exposure.
The study assessed two ketamine doses, one resembling the dose used in depression treatment and another simulating anesthesia. The effects on the dopamine system were evident at both doses.
According to Yannan Chen, co-author of the paper, this study represents a technological breakthrough in high-resolution brain studies. It is the first successful attempt to map changes induced by chronic ketamine exposure at a sub-cellular resolution, enabling researchers to observe ketamine’s effects on individual cells.
Bradley Miller, a Columbia psychiatrist and neuroscientist specializing in depression, commented on the study’s significance. Ketamine has shown rapid antidepressant effects and is being explored for long-term depression prevention. Understanding how ketamine rewires the brain through repeated use is crucial for developing targeted treatments with fewer side effects.
The study’s lead authors, Malika Datta and Yannan Chen, conducted their research in Raju Tomer’s lab at Columbia. Datta is currently a postdoctoral fellow at Yale.
In summary, this groundbreaking study provides a comprehensive understanding of ketamine’s effects on the brain. The findings have the potential to contribute to improved clinical applications of ketamine while minimizing its recreational abuse. The study also highlights the varying responses of neurons in different brain regions to the same drug, contributing to a deeper understanding of the brain’s complexity.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
